Crystal Structures and Physicochemical Properties of Solvated Estradiol

被引:0
作者
Wang Hui-Ping [1 ]
Xu Juan [1 ]
Ning Li-Feng [1 ]
Li Peng [1 ]
Chen Xiao-Feng [1 ]
机构
[1] Natl Res Inst Family Planning, Beijing 100081, Peoples R China
基金
国家重点研发计划;
关键词
estradiol; crystalline structure; solubility; stability; SOLID-STATE; STEROID-HORMONES; POLYMORPHISM; 17-BETA-ESTRADIOL; ABSORPTION; BIOAVAILABILITY; CONTRACEPTIVES; SPECTROSCOPY; BIOSENSOR; IMPACT;
D O I
10.14102/j.cnki.0254-5861.2011-1946
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
Polymorph screening is currently one of the most important tasks for innovators and for generic companies from both pharmaceutical and intellectual property rights aspects. The hemihydrate form (Form I) and formamide solvate (Form II) of estradiol are isolated and prepared via systemic crystallization screening in this paper, and the formamide solvate form is reported for the first time. Both polymorphic forms were characterized by single-crystal X-ray structure analysis (SXRD), powder X-ray diffraction (PXRD), and thermal analysis (TGA and DSC). The PXRD experiments indicate that the samples in this study are the pure polymorphic forms via comparing the patterns with the simulated ones. The stability and equilibrium solubility data of the solid-state phase were also examined in order to check the impact of the differences observed in their crystalline structures. It has been found that Forms I and II are of conformational polymorph and Form II is the more thermodynamically stable solid form, while Form I possesses higher solubility, indicating its possibility as an alternate solid form for its further solid formulation development if necessary.
引用
收藏
页码:730 / 740
页数:11
相关论文
共 42 条
[31]   Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids [J].
Shah, Birju ;
Kakumanu, Vasu Kumar ;
Bansal, Arvind K. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (08) :1641-1665
[32]  
Shapiro S, 2000, AM J EPIDEMIOL, V151, P396, DOI 10.1093/oxfordjournals.aje.a010219
[33]   Oral contraceptives - Risks [J].
Shulman, LP .
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2000, 27 (04) :695-+
[34]   Drug polymorphism and dosage form design: a practical perspective [J].
Singhal, D ;
Curatolo, W .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (03) :335-347
[35]   Characterization of the solid state: quantitative issues [J].
Stephenson, GA ;
Forbes, RA ;
Reutzel-Edens, SM .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 48 (01) :67-90
[36]  
Sudha R. V., 2001, ADV DRUG DELIV REV, V48, P3
[37]   Benefits and Limitations of Polymorphic and Amorphous Forms of Active Pharmaceutical Ingredients [J].
Talaczynska, Alicja ;
Dzitko, Jakub ;
Cielecka-Piontek, Judyta .
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (32) :4975-4980
[38]   Characterization of crystal forms of β-estradiol -: thermal analysis, Raman microscopy, X-ray analysis and solid-state NMR [J].
Variankaval, NE ;
Jacob, KI ;
Dinh, SM .
JOURNAL OF CRYSTAL GROWTH, 2000, 217 (03) :320-331
[39]   Polymorphism of 17-β estradiol in a transdermal drug delivery system [J].
Variankaval, NE ;
Jacob, KI ;
Dinh, SM .
JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 2002, 13 (03) :271-280
[40]   Crystalline solids [J].
Vippagunta, SR ;
Brittain, HG ;
Grant, DJW .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 48 (01) :3-26